Jonathan Silverstein

Jonathan T. Silverstein, J.D./M.B.A., is a former Managing Partner and Co-Head of Global Private Equity at OrbiMed. He is currently an Executive Partner at OrbiMed, one of the world’s largest fully dedicated healthcare fund managers. Silverstein joined OrbiMed in 1999 and has been on the board of several dozen biotech companies over the last two decades. During his tenure, OrbiMed invested in healthcare companies that have led to over 60 FDA-approved therapeutics, medical devices, and diagnostics.

With a particular interest in rare diseases, Silverstein was the chairman of several biotechnology companies focused on these “orphan” drugs, including Enobia (sold to Alexion) and Intercept (ICPT), and a director of Ascendis (ASND) and Rhythm Therapeutics (RYTM). For seven consecutive years, Forbes Magazine named Silverstein one of the top 100 venture capitalists in the world when it placed him on the “Forbes Midas List.”

After being diagnosed with Parkinson’s Disease, Silverstein learned that he was a carrier of the GBA mutation that had triggered his disease. He established The Silverstein Foundation for Parkinson’s with GBA and began working with a team of the world’s leading GBA-PD experts to help him find a cure. Over his 20 years of experience in healthcare venture capital, Silverstein has had success in investing in therapeutics to treat PD and other rare diseases, making him well-positioned to take on this challenge.

Silverstein has a J.D. and an M.B.A. from the University of San Diego, as well as a B.A. in Economics from Denison University.